Please login to the form below

Not currently logged in
Email:
Password:

bladder cancer

This page shows the latest bladder cancer news and features for those working in and with pharma, biotech and healthcare.

Roche builds on Immunocore ImmTAC deal

Roche builds on Immunocore ImmTAC deal

The trial is scheduled to start in early 2019, and will include a host of cancers, including non-small cell lung cancer (NSCLC), bladder cancer, head and neck cancer, gastric cancer ... Those molecules are based on soluble, engineered TCR’s, which

Latest news

  • AZ’s MYSTIC survival data is in – and it’s a bust AZ’s MYSTIC survival data is in – and it’s a bust

    Imfinzi failed to achieve OS improvement. AstraZeneca has released the overall survival (OS) data from its MYSTIC trial of Imfinzi and tremelimumab in advanced non-small cell lung cancer (NSCLC), and ... In the meantime, AZ also has trials of Imfinzi

  • Roche gains speedy review for Tecentriq in first-line breast cancer Roche gains speedy review for Tecentriq in first-line breast cancer

    Tecentriq in combination with nab-paclitaxel has the potential to meaningfully advance treatment for people with PD-L1-positive, metastatic triple-negative breast cancer. ... Tecentriq is already approved in the US for certain types of bladder cancer and

  • Ocrevus surge keeps Roche smiling in Q3 Ocrevus surge keeps Roche smiling in Q3

    However, the performance of Ocrevus and other drugs such as HER2 breast cancer therapy Perjeta (pertuzumab) and lung cancer therapy Alecensa (alectinib) – plus a strong showing in Asia-Pacific markets led ... The none-month figures show some headway in

  • A look ahead to key trial readouts at ESMO A look ahead to key trial readouts at ESMO

    It  will also have mid-stage data on the drug as a first-line monotherapy for non-muscle invasive bladder cancer (KEYNOTE-057). ... VEGF/FGF/PDGF inhibitor will give an update on lucitanib – also in HR+/HER2- breast cancer.

  • Imfinzi aces survival challenge in lung cancer Imfinzi aces survival challenge in lung cancer

    Earlier treatment leads to much extended lives, data suggests. Long-awaited data from AstraZeneca’s Imfinzi suggest it could become an entirely new standard treatment for mid-stage lung cancer patients ... second-line head and neck cancer, small cell

More from news
Approximately 20 fully matching, plus 91 partially matching documents found.

Latest Intelligence

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    had transformative results in some diseases such as melanoma, non-small cell lung cancer and bladder cancer – among others. ... Cavatak is now in three trials in melanoma, bladder cancer and NSCLC that are due to generate results in 2018/2019.

  • Deal Watch October 2015 Deal Watch October 2015

    Immunomic Therapeutics will retain the rights to its LAMP-vax platform for other applications, including cancer immunotherapy. ... MCNA for non-muscle invasive bladder cancer  (BLA filed). Licence. 137. Proteros biostructures/ Merck &Co.

  • Interview: Trevor Smith, Takeda Interview: Trevor Smith, Takeda

    There's prostate cancer drug orteronel (TAK-700) and vedolizumab for Crohn's disease and ulcerative colitis, and then the atypical antipsychotic lurasidone. ... drug and the risk of bladder cancer.

  • Country report: The healthcare market in Japan Country report: The healthcare market in Japan

    The largest therapeutic category is Renin-angiotensin system agents (antihypertensive), followed by anti-neoplastics (cancer drugs).  . ... bladder cancer.

  • Achieving consensus

    Their joint aim: to facilitate uniform use of fluorescence cystoscopy in the diagnosis and follow up of bladder cancer, with the ultimate goal of improved care and better outcomes for patients. ... Despite widespread acceptance of the evidence for

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest from PMHub

  • A reflection of ESMO

    The objective for this congress is for HCPs to learn from physicians and scientists who present their research in prostate, bladder, and kidney cancer. ... highlighting the ground-breaking research in cancer care.

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M3 (EU)

M3 was founded in 2000 with the goal of changing the world of medicine through making full use of the...

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics